Re-examining the lymph node surgical strategies for small-cell cervical cancer: shifting from local intervention to a systemic paradigm

Dear Editor, The study by Huang et al[1] on the value of lymphadenectomy in small-cell cervical cancer (SCCC) provides valuable evidence-based insights. The dual-cohort design and rigorous statistical analysis are commendable. However, this research exposes fundamental limitations in our current understanding of this rare yet highly aggressive malignancy, necessitating reflection across three interconnected dimensions. This letter complies with the TITAN Guidelines 2025 on transparency of artificial intelligence (AI) use; not a single AI tool was used in its creation[2]. First, this study continues the research paradigm established for squamous cell cervical carcinoma, evaluating lymph nodes (LNs) dissection as an extension of local therapy while overlooking SCCC’s core biological trait: its propensity for early hematogenous micrometastasis[3,4]. As the authors rightly note, SCCC may be more prone to early hematogenous spread (e.g. to lung, liver, bone) rather than primarily spreading via lymphatic routes[5]. This crucial insight fundamentally challenges the study’s premise: in the era of systemic therapy, should we still approach SCCC as a locoregional disease warranting aggressive surgical intervention? Instead of debating surgical details, a more fundamental question should be whether the value hierarchy of radical primary surgery in SCCC’s multimodal treatment needs re-evaluation. For a malignancy driven by systemic spread, local treatments must be evaluated in the context of systemic therapy synergy. We may need to move beyond traditional surgical paradigms for cervical cancer (CC) and design prospective trials directly comparing “surgery-first” versus “systemic therapy-first” strategies to truly determine the optimal initial treatment pathway for SCCC. Second, as immunotherapy reshapes the treatment landscape of advanced CC, our perception of LNs’ roles must evolve. Although the study acknowledges immunotherapy’s potential, it fails to reframe the research questions accordingly. Critically, LNs are not merely “indicators” of metastatic risk; they also serve as “command centers” for antitumor immune responses[6]. In an era where PD-1/PD-L1 inhibitors have become standard therapy for advanced CC[7], routine lymphadenectomy may inadvertently undermine the potential efficacy of subsequent immunotherapy. Emerging evidence highlights that the structural integrity of tumor-draining LNs is critical for immunotherapy outcomes, as these nodes serve as pivotal sites where dendritic cells present tumor antigens to naïve T cells, thereby triggering their activation and differentiation, and thus their excision may compromise endogenous antitumor capacity. The study does not distinguish between “structural LNs removal” and “functional LNs status,” overlooking that even pathologically negative nodes, when physically excised, can disrupt the antigen-presentation cascade[8]. Conversely, in the immunotherapy era, the presence of positive nodes may represent a therapeutic target rather than a surgical indication. This perspective, however, may limit the direct translation of the study’s findings into contemporary clinical practice, where immunotherapy is increasingly integrated. Third, the study’s conclusion that “routine LN dissection provides no survival benefit in FIGO I–IVA SCCC patients,” while statistically robust, may obscure a core dilemma of the precision-medicine era: heterogeneity in rare tumors. A one-size-fits-all conclusion simplifies clinical decision-making but forfeits the opportunity to identify truly benefitting subgroups. Given the extreme rarity of SCCC, we must move beyond the traditional binary framework of “dissect versus not dissect” and instead construct adaptive decision-making models based on molecular subtypes and metastatic patterns[9,10]. For example, a lymphatic-predominant subtype (characterized by high lymphatic vessel density and confined regional nodal spread) may still warrant dissection; a hematogenous-predominant subtype (with positron emission tomography-computed tomography evidence of multiorgan micro-metastases) should avoid dissection and prioritize systemic therapy; and an immune-active subtype (with high tumor mutational burden, PD-L1 positivity) should preserve draining LN to enable subsequent immunotherapy. Such stratified thinking does not refute the study’s findings but elevates them into a practical framework for personalized care, thereby channeling the insight from “no benefit at the population level” directly towards “precision intervention in specific subgroups.” Collectively, the value of this study lies not only in its specific findings but also in how it compels us to rethink the therapeutic philosophy for SCCC. Moving forward, we need to: (1) re-evaluate the priority of local surgery in a systemic disease; (2) redefine the functional value of LNs in antitumor immunity; and (3) transcend one-size-fits-all conclusions by pursuing biomarker-defined subgroups. Integrating these perspectives will shift the paradigm from “anatomic completeness” to “biological rationale.” International, multi-omics prospective trials are urgently needed to build a personalized treatment roadmap for this aggressive, rare cancer.